Evidence map›Paper›PMID 40629152›Full record

ArticleThe Journal of infectious diseases2025

Clinical and Genomic Characterization of Recalcitrant Enterococcal Bacteremia: A Multicenter Prospective Cohort Study (VENOUS).

Shelby R Simar, Truc T Tran, Kirsten B Rydell, Rachel L Atterstrom, Pranoti V Sahasrabhojane, An Q Dinh, Marissa G Schettino, Haley S Slanis, Alex E Deyanov, Andie M DeTranaltes and 20 more

Abstract readMulticenter Study
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Shelby R SimarCenter for Infectious Diseases, University of Texas Health-Houston School of Public Health, Houston, Texas, USA.
Truc T TranDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Kirsten B RydellDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Rachel L AtterstromDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Pranoti V SahasrabhojaneDepartment of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
An Q DinhDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-2965-9269
Marissa G SchettinoDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0009-0006-0461-399X
Haley S SlanisDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Alex E DeyanovDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-7579-2351
Andie M DeTranaltesDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0009-0004-2061-308X
Dierdre B Axell-HouseDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
William R MillerDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Jose M MunitaGenomics and Resistant Microbes Group, Facultad de Medicina Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.ORCID 0000-0002-7870-1056
David TobysInstitute for Medical Microbiology, Immunology, and Hygiene, Medical Faculty, University Hospital Cologne, Cologne, Germany.
Harald SeifertInstitute for Medical Microbiology, Immunology, and Hygiene, Medical Faculty, University Hospital Cologne, Cologne, Germany.ORCID 0000-0002-7732-4762
Lena M BiehlGerman Center for Infection Research, Healthcare-Associated Infections, Partner Site Bonn-Cologne, Cologne, Germany.ORCID 0000-0001-7613-8119
Marcus ZervosDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.ORCID 0000-0002-7328-4898
Geehan SuleymanDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
Jagjeet KaurDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.ORCID 0000-0002-6801-8130
Victoria WarzochaDepartment of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.ORCID 0009-0007-9408-7192
Rossana RosaJackson Health System, Miami Transplant Institute, Miami, Florida, USA.ORCID 0000-0002-3755-7780
Renzo O CifuentesJackson Health System, Miami Transplant Institute, Miami, Florida, USA.
Lilian M AbboJackson Health System, Miami Transplant Institute, Miami, Florida, USA.ORCID 0000-0002-2364-8358
Luis ShimoseDivision of Infectious Disease, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Catherine LiuDepartment of Medicine, Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-7532-4822
Katherine NguyenDepartment of Medicine, Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, Washington, USA.
Ashleigh MillerDepartment of Medicine, Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0009-0009-9258-9855
Samuel A ShelburneDepartment of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9721-263X
Blake M HansonCenter for Infectious Diseases, University of Texas Health-Houston School of Public Health, Houston, Texas, USA.ORCID 0000-0003-2949-7818
Cesar A AriasDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0001-9054-9774

Funding

Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HAAG, ANTHONY · 2020 to 2025
$12.0M
VENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9M
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
Molecular Basis of Infectious Diseases Training GrantT32AI055449 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LORENZ, MICHAEL C · 2005 to 2025
$2.6M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
Mobile Genetic Elements and Clinical Outcomes in Staphylococcus aureus BacteremiaK01AI148593 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HANSON, BLAKE M · 2020 to 2023
$519k
National Institute of Allergy and Infectious Disease K01AI148593-01National Institute of Allergy and Infectious Disease K24AI121296National Institute of Allergy and Infectious Disease P01AI152999-01National Institute of Allergy and Infectious Disease R01AI134637National Institute of Allergy and Infectious Disease R01AI148342-01NIAID NIH HHS K01 AI148593NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS T32 AI055449NIAID NIH HHS T32 AI141349NIH HHS 5T32AI055449-15
6 · The paper itself

Abstract

backgroundPatients with recalcitrant enterococcal bloodstream infections are at greater risk of adverse outcomes. We identified patients in the 2016-2022 Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS) cohort experiencing recalcitrant bloodstream infections for further clinical and genomic characterization.

methodsBacteremia episodes were considered persistent if there was a lack of clearance on day 4 while receiving ≥ 48 hours of active therapy and recurrent if there was clearance during hospitalization with a subsequent positive culture (collectively, recalcitrant bacteremia). A matched comparison group of nonrecalcitrant bacteremia patients was chosen in a 2:1 control to case ratio. Isolates were subjected to short- and long-read whole-genome sequencing. Hybrid assemblies were created using a custom pipeline.

resultsA total of 46 recalcitrant infections from 41 patients were identified. Patients with persistent bacteremia were more often admitted to the intensive care unit upon admission relative to controls. Enterococcus faecalis strains causing persistent infections had a significantly higher proportion of genes associated with carbohydrate utilization relative to controls. Representation of functional groups associated with mutated genes was disparate between Enterococcus faecium and E. faecalis index and persistent isolates, suggesting species-specific adaptation. DISCUSSION: Enterococcal isolates causing recalcitrant bacteremia were genomically diverse, indicating that strain-specific signatures are not drivers of persistence. However, comparisons of index versus persistent isolates revealed that E. faecium may be genetically preadapted to cause persistent infection, and site-specific structural variation during infection suggests the role of differential gene expression in adaptation and persistence. These data lay groundwork for future studies to define signatures of enterococcal adaptation during bacteremia.

Indexed as

BacteremiaGram-Positive Bacterial InfectionsVancomycin-Resistant EnterococciAdultAgedAnti-Bacterial AgentsEnterococcus faecalisEnterococcus faeciumFemaleGenome, BacterialGenomicsHumansMaleMiddle AgedProspective StudiesWhole Genome SequencingAnti-Bacterial AgentsEnterococcus; bacteremiagenomic adaptationpersistent infection

Identifiers

PMID40629152
PMCPMC12718003

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.